Cited by 126Substance Abuse Treatment and OutcomesOpioid Use Disorder TreatmentChronic Disease Management Strategies

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Alcohol, Cannabis, and Opioid Use Disorders, and Disease Burden in an Integrated Health Care System

Open access

Bahorik, Amber L., Satre, Derek D., Kline-Simon, Andrea H., Weisner, Constance M., Campbell, Cynthia I.·2017·Journal of Addiction Medicine

DOI 10.1097/adm.0000000000000260PMC PMC5291754

Open this paper in CoChat — free account

Abstract

OBJECTIVES: We examined prevalence of major medical conditions and extent of disease burden among patients with and without substance use disorders (SUDs) in an integrated health care system serving 3.8 million members. METHODS: Medical conditions and SUDs were extracted from electronic health records in 2010. Patients with SUDs (n = 45,461; alcohol, amphetamine, barbiturate, cocaine, hallucinogen, and opioid) and demographically matched patients without SUDs (n = 45,461) were compared on the prevalence of 19 major medical conditions. Disease burden was measured as a function of 10-year mortality risk using the Charlson Comorbidity Index. P-values were adjusted using Hochberg's correction for multiple-inference testing within each medical condition category. RESULTS: The most frequently diagnosed SUDs in 2010 were alcohol (57.6%), cannabis (14.9%), and opioid (12.9%). Patients with these SUDs had higher prevalence of major medical conditions than non-SUD patients (alcohol use disorders, 85.3% vs 55.3%; cannabis use disorders, 41.9% vs 23.0%; and opioid use disorders, 44.9% vs 26.1%; all P < 0.001). Patients with these SUDs also had higher disease burden than non-SUD patients; patients with opioid use disorders (M = 0.48; SE = 1.46) had particularly high disease burden (M = 0.23; SE = 0.09; P < 0.001). CONCLUSIONS: Common SUDs, particularly opioid use disorders, are associated with substantial disease burden for privately insured individuals without significant impediments to care. This signals the need to explore the full impact SUDs have on the course and outcome of prevalent conditions and initiate enhanced service engagement strategies to improve disease burden.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/adm.0000000000000260

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Extent of illicit drug use and dependence, and their contribution to the global burden of disease
Degenhardt, L. J., & Hall, W. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61138-0 · Cited by 1,354
Adverse health effects of non-medical cannabis use
Hall, W., & Degenhardt, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61037-0 · Cited by 1,134
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,014
The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients
Charlson, M. E., Charlson, R. E., Peterson, J. C., Marinopoulos, S. S., Briggs, W. M., & Hollenberg, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.01.006 · Cited by 894 · cited 4×
“This measure yields a weighted score predicting 10-year mortality risk for patients who present for treatment with a range of diagnosis-based comorbid medical conditions (Charlson et al., 2008).”
BackgroundMethodInfluential
Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010
Degenhardt, L. J., Whiteford, H., Ferrari, A. J., Baxter, A. J., Charlson, F., Hall, W., Freedman, G., Burstein, R., Johns, N. E., Engell, R. E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61530-5 · Cited by 873
Alcohol-use disorders
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 715
Societal costs of prescription opioid abuse, dependence, and misuse in the United States
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M., & Roland, C. L. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01075.x · Cited by 644

Show all 33 references

Sorted by citations

COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States
Wang, Q. Q., Kaelber, D. C., Xu, R., & Volkow, N. D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00880-7 · Cited by 634
Alcohol and Opioid Use, Co‐Use, and Chronic Pain in the Context of the Opioid Epidemic: A Critical Review
Witkiewitz, K., & Vowles, K. E. (2018) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13594 · Cited by 248
The neurobiology of addiction
Uhl, G. R., Koob, G. F., & Cable, J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13989 · Cited by 286
Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries
Fond, G. B., Nemani, K., Etchecopar‐Etchart, D., Loundou, A., GOFF, D. C., Lee, S. W., Lançon, C., Auquier, P., Baumstarck, K., Llorca, P., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.2274 · Cited by 228
Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada
Ali, F., Russell, C., Nafeh, F., Rehm, J. T., LeBlanc, S., & Elton‐Marshall, T. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103237 · Cited by 172
The efficacy of spiritual/religious interventions for substance use problems: A systematic review and meta-analysis of randomized controlled trials
Hai, A. H., Franklin, C., Park, S., DiNitto, D. M., & Aurelio, N. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.04.045 · Cited by 139
Mindfulness meditation in the treatment of substance use disorders and preventing future relapse: neurocognitive mechanisms and clinical implications
Priddy, S. E., Howard, M. O., Hanley, A. W., Riquino, M. R., Friberg-Felsted, K., & Garland, E. L. (2018) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s145201 · Cited by 101
Low Barrier Tele-Buprenorphine in the Time of COVID-19: A Case Report
Harris, M. T. H., Johnson, S., Mackin, S., Saitz, R., Walley, A. Y., & Taylor, J. L. (2020) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000682 · Cited by 95
Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review
Bahji, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040999 · Cited by 83
“Studies have shown that individuals receiving integrated care experience enhanced treatment engagement, reduced substance use, improved mental health, and an overall better quality of life [20,21].”
Background
Development and use of a toolkit to facilitate implementation of an evidence-based intervention: a descriptive case study
Thoele, K., Ferren, M. D., Moffat, L., Keen, A., & Newhouse, R. (2020) · Implementation Science Communications · doi:10.1186/s43058-020-00081-x · Cited by 68
Socioeconomic Disparities and Self-reported Substance Abuse-related Problems.
Baptiste-Roberts, K., & Hossain, M. B. (2018) · Europe PMC (PubMed Central) · doi:10.22122/ahj.v10i2.561 · Cited by 73
Prevalence of documented alcohol and opioid use disorder diagnoses and treatments in a regional primary care practice-based research network
Hallgren, K. A., Witwer, E., West, I. I., Baldwin, L., Donovan, D. M., Stuvek, B., Keppel, G. A., Mollis, B. L., & Stephens, K. A. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.11.008 · Cited by 60
Advances in the delivery of buprenorphine for opioid dependence
Rosenthal, R. N., & Goradia, V. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s72543 · Cited by 59
Effectiveness of the use of implementation intentions on reduction of substance use: A meta-analysis
Malaguti, A., Ciocanel, O., Sani, F., Dillon, J. F., Eriksen, A., & Power, K. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108120 · Cited by 48
Psychiatry Trainees' Attitudes, Knowledge, and Training in Addiction Psychiatry—A European Survey
Orsolini, L., Palavra, I. R., Papanti, G. D., Potočan, M., Quattrone, D., Martens, M., Sklenářová, S., Levola, J. M., Grichy, L., Naughton, S., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.585607 · Cited by 38
Facing the option for the legalisation of cannabis use and supply in New Zealand: An overview of relevant evidence, concepts and considerations
Fischer, B., Daldegan‐Bueno, D., & Boden, J. M. (2020) · Drug and Alcohol Review · doi:10.1111/dar.13087 · Cited by 38
Frequencies of emergency department use and hospitalization comparing patients with different types of substance or polysubstance-related disorders
Armoon, B., Grenier, G., Cao, Z., Huỳnh, C., & Fleury, M. (2021) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-021-00421-7 · Cited by 37
An Islamic Spiritual Alternative to Addiction Treatment and Recovery
Bensaid, B., Machouche, S., & Tekke, M. (2021) · Al-Jami ah Journal of Islamic Studies · doi:10.14421/ajis.2021.591.127-162 · Cited by 32
The role of marijuana use disorder in predicting emergency department and inpatient encounters: A retrospective cohort study
Campbell, C. I., Bahorik, A. L., Kline‐Simon, A. H., & Satre, D. D. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.04.017 · Cited by 30
Self-citation
Alcohol, Marijuana, and Opioid use Disorders: 5-Year Patterns and Characteristics of Emergency Department Encounters
Bahorik, A. L., Satre, D. D., Kline‐Simon, A. H., Weisner, C. M., Young‐Wolff, K. C., & Campbell, C. I. (2017) · Substance Abuse · doi:10.1080/08897077.2017.1356789 · Cited by 31
Self-citation
Opioid and Polydrug Use Among Patients in Opioid Maintenance Treatment
Carlsen, S.-E. L., Lunde, L.-H., & Torsheim, T. (2020) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s221618 · Cited by 30
Facilitators and barriers to utilization of medications for opioid use disorder in primary care in South Carolina
Oros, S. M., Christon, L., Barth, K. S., Berini, C., Padgett, B. L., & Díaz, V. A. (2020) · The International Journal of Psychiatry in Medicine · doi:10.1177/0091217420946240 · Cited by 26
Cannabis use disorder and substance use treatment among U.S. adults
Choi, N. G., Moore, J., & Choi, B. Y. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209486 · Cited by 22
Clinical impact of COVID-19 on people with substance use disorders
Vallecillo, G., Perelló, R., Güerri, R., Fonseca, F., & Torrens, M. (2020) · Journal of Public Health · doi:10.1093/pubmed/fdaa181 · Cited by 22
Risk Factors for Death Among Hospitalized Patients Aged 21–64 Years Diagnosed with COVID-19—New York City, March 13–April 9, 2020
Bushman, D., Davidson, A., Pathela, P., Greene, S. K., Weiss, D., Reddy, V., New York City Fatal Case-Control St Team, & Latash, J. (2021) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-021-01098-1 · Cited by 21
The Prevalence of Healthcare Effectiveness Data and Information Set (Hedis) Initiation and Engagement in Treatment among Patients with Cannabis Use Disorders in 7 Us Health Systems
Lapham, G. T., Campbell, C. I., Yarborough, B. J. H., Hechter, R. C., Ahmedani, B. K., Haller, I. V., Kline‐Simon, A. H., Satre, D. D., Loree, A. M., Weisner, C. M., et al. (2019) · Substance Abuse · doi:10.1080/08897077.2018.1544964 · Cited by 21
Self-citation
Prevalence of Mental Health Disorders among Individuals Enrolled in an Emergency Response Program for Treatment of Opioid Use Disorder
Bakos‐Block, C., Langabeer, J. R., Yatsco, A. J., Cárdenas-Turanzas, M., & Champagne‐Langabeer, T. (2020) · Substance Abuse Research and Treatment · doi:10.1177/1178221820981998 · Cited by 21
COVID ‐19 vaccination coverage and vaccine hesitancy among people with opioid use disorder in Barcelona, Spain
Vallecillo, G., Durán, X., Canosa, I., Roquer, A., Martinez, M. C., & Perelló, R. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13502 · Cited by 20
Alcohol Problems among Prisoners: Subgroup Variations, Concurrent Drug Problems, and Treatment Needs
Pape, H., Rossow, I. M., & Bukten, A. (2020) · European Addiction Research · doi:10.1159/000511253 · Cited by 23
Patients admitted to treatment for substance use disorder in Norway: a population-based case–control study of socio-demographic correlates and comparative analyses across substance use disorders
Amundsen, E. J., Bretteville‐Jensen, A. L., & Rossow, I. M. (2022) · BMC Public Health · doi:10.1186/s12889-022-13199-5 · Cited by 24
Using mind control to modify cue-reactivity in AUD: the impact of mindfulness-based relapse prevention on real-time fMRI neurofeedback to modify cue-reactivity in alcohol use disorder: a randomized controlled trial
Weiß, F., Aslan, A., Zhang, J., Gerchen, M. F., Kiefer, F., & Kirsch, P. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02717-7 · Cited by 21
Risk factors for COVID-19 among persons with substance use disorder (PWSUD) with hospital visits – United States, April 2020–December 2020
Amy Board, Kim, S.-K., Park, J., Schieber, L. Z., Miller, G. F., Pike, J. J., Cremer, L. J., & Asher, A. K. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109297 · Cited by 19
Rural communities face more than an opioid crisis: Reimagining funding assistance to address polysubstance use, associated health problems, and limited rural service capacity
Mun, C. C., Schuler, H., Baker, R., Byrne, F. R., Bresani, E., & Meyers, K. (2023) · The Journal of Rural Health · doi:10.1111/jrh.12743 · Cited by 18
Identifying barriers and facilitators to COVID-19 vaccination uptake among People Who Use Drugs in Canada: a National Qualitative Study
Ali, F., Kaura, A., Russell, C., Bonn, M., Bruneau, J., Dasgupta, N., Imtiaz, S., Martel‐Laferrière, V., Rehm, J. T., Shahin, R., et al. (2023) · Harm Reduction Journal · doi:10.1186/s12954-023-00826-6 · Cited by 18
Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only
Aquino, J. P. D., Sofuoglu, M., Stefanovics, E. A., & Rosenheck, R. A. (2019) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2019.1607363 · Cited by 20
CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder
Nagamatsu, S. T., Rompala, G. R., Hurd, Y. L., Núñez-Ríos, D. L., & Montalvo‐Ortiz, J. L. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1078894 · Cited by 17
Converging Crises: Caring for Hospitalized Adults With Substance Use Disorder in the Time of COVID‐19
Englander, H. L., Salisbury‐Afshar, E., Gregg, J. L., Martín, M., Snyder, H. R., Weinstein, Z., & King, C. A. (2020) · Journal of Hospital Medicine · doi:10.12788/jhm.3485 · Cited by 17
Repeated ethanol exposure and withdrawal alters angiotensin‐converting enzyme 2 expression in discrete brain regions: Implications for SARS‐CoV ‐2 neuroinvasion
Balasubramanian, N., James, T. D., Selvakumar, G. P., Reinhardt, J., & Marcinkiewcz, C. A. (2022) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15000 · Cited by 17
Prevalence of Substance Use Disorders in Sickle Cell Disease Compared to Other Chronic Conditions: a Population-Based Study of Black American Adults
Jonassaint, C. R., O’Brien, J. A., Nardo, E., Feldman, R., Stanton, M. V., DeCastro, L. M., & Abebe, K. Z. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07786-w · Cited by 16
Political partisanship and stigma against people who use drugs in opinions about allocating COVID-19 prevention resources to vulnerable populations
Schneider, K. E., Wilson, D. H., Dayton, L., Goodell, E. M. A., & Latkin, C. A. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103301 · Cited by 16
Individual and social network correlates of recent treatment for substance use disorders among persons who use drugs in Baltimore, MD (2014 – 2017)
Rudolph, A. E., Fernau, D. J., Tobin, K. E., & Latkin, C. A. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108278 · Cited by 16
Healthcare coverage and service access for low-income adults with substance use disorders
Olfson, M., Mauro, C., Wall, M. M., Choi, C. J., Barry, C. L., & Mojtabai, R. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108710 · Cited by 15
Occupational Therapy’s Role in Chronic Conditions
Lambdin-Pattavina, C. A., & Pyatak, E. A. (2022) · American Journal of Occupational Therapy · doi:10.5014/ajot.2022.76s3003 · Cited by 15
Shared orbitofrontal dynamics to a drug-themed movie track craving and recovery in heroin addiction
Kronberg, G., Ceceli, A. O., Huang, Y., Gaudreault, P., King, S. G., McClain, N. E., Nelly Alia-klein, A., & Goldstein, R. Z. (2024) · Brain · doi:10.1093/brain/awae369 · Cited by 14
Sex-Dependent Synergism of an Edible THC: CBD Formulation in Reducing Anxiety and Depressive-like Symptoms Following Chronic Stress
Pérez-Valenzuela, E., Hudson, R., Uzuneser, T. C., Felice, M. D., Szkudlarek, H. J., Rushlow, W. J., & Laviolette, S. R. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230912101441 · Cited by 13
Quickly identifying people at risk of opioid use disorder in emergency departments: trade-offs between a machine learning approach and a simple EHR flag strategy
Annis, I. E., Jordan, R., & Thomas, K. C. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059414 · Cited by 14
Proposing a “Brain Health Checkup (BHC)” as a Global Potential “Standard of Care” to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of “Dopamine Homeostasis”
Braverman, E. R., Dennen, C. A., Gold, M. S., Bowirrat, A., Gupta, A., Baron, D. A., Roy, A., Smith, D. E., Cadet, J. L., & Blum, K. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19095480 · Cited by 14
Medical cannabis use among individuals with cancer: An unresolved and timely issue
Nugent, S. M., Meghani, S. H., Rogal, S. S., & Merlin, J. S. (2020) · Cancer · doi:10.1002/cncr.32732 · Cited by 14
High cardiovascular risk in older patients with opioid use disorder: Differences with the general population
Vallecillo, G., Pedro‐Botet, J., Fernández, S. F., Román, I., Elosúa, R., Camps, A., Torrens, M., & Marrugat, J. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13449 · Cited by 12
Kidney Disease among People Who Are Incarcerated
Murphy, M., Ding, A., Berk, J., Rich, J., & Bayliss, G. (2021) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01910221 · Cited by 11
One Third of Alcohol Use Disorder Diagnoses are Missed by ICD Coding
Mercurio, L. Y., Garcia, A., Ruest, S. M., Duffy, S. J., & Eickhoff, C. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342241288112 · Cited by 10
Alcohol and Drug Use, Pain and Psychiatric Symptoms among Adults Seeking Outpatient Psychiatric Treatment: Latent Class Patterns and Relationship to Health Status
Ramo, D. E., Bahorik, A. L., Delucchi, K., Campbell, C. I., & Satre, D. D. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1401185 · Cited by 10
Self-citation
Systematic review of guidelines for managing physical health during treatment for substance use disorders: Implications for the alcohol and other drug workforce
Osborne, B. A., Larance, B., Ivers, R. G., Deane, F. P., Robinson, L. D., & Kelly, P. J. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13504 · Cited by 9
The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder
Ober, A. J., Murray-Krezan, C. M., Page, K. A., Friedmann, P. D., Osilla, K. C., Ryzewicz, S., Huerta, S., Mazer, M. W., Leamon, I. M., Messineo, G., et al. (2022) · Addiction Science & Clinical Practice · doi:10.1186/s13722-022-00320-7 · Cited by 9
Association between cannabis use disorder symptom severity and probability of clinically-documented diagnosis and treatment in a primary care sample
Matson, T. E., Williams, E. C., Lapham, G. T., Oliver, M. M., Hallgren, K. A., & Bradley, K. A. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110946 · Cited by 9
Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders
Hammond, C. J., Park, G. S. H., Kady, A., Rathod, K., Rahman, N., Vidal, C., Wenzel, K. R., & Fishman, M. J. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108495 · Cited by 7
Supporting Providers After Drug Overdose Death
Yule, A. M., & LEVIN, F. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070794 · Cited by 9
Correction to: Risk Factors for Death Among Hospitalized Patients Aged 21–64 Years Diagnosed with COVID-19—New York City, March 13–April 9, 2020
Bushman, D., Davidson, A., Pathela, P., Greene, S. K., Weiss, D., Reddy, V., New York City Fatal Case-Control Study Team, & Latash, J. (2021) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-021-01139-9 · Cited by 9
Meta‐Analysis of Integrated Primary and Behavioral Health Care Interventions for Treating Substance Use Among Adults
Balkin, R. S., Lenz, A. S., Dell’Aquila, J., Gregory, H. M., Rines, M. N., & Swinford, K. E. (2019) · Journal of Addictions & Offender Counseling · doi:10.1002/jaoc.12067 · Cited by 8
Managing Substance Use Disorder through a Walking/Running Training Program
Dai, C., Chen, C., Richardson, G. B., & Gordon, H. R. D. (2020) · Substance Abuse Research and Treatment · doi:10.1177/1178221820936681 · Cited by 8
Communication of health risk in substance‐dependent populations: A systematic review of randomised controlled trials
Goh, M. C. W., Kelly, P. J., Deane, F. P., Raftery, D., & Ingram, I. (2021) · Drug and Alcohol Review · doi:10.1111/dar.13249 · Cited by 8
Integrating Social Determinants of Health and Laboratory Data: A Pilot Study To Evaluate Co-Use of Opioids and Benzodiazepines
Warrington, J. S., Lovejoy, N., Brandon, J., Lavoie, K., & Powell, C. (2019) · Academic Pathology · doi:10.1177/2374289519884877 · Cited by 9
Using Economic Evaluation to Inform Responses to the Opioid Epidemic in the United States: Challenges and Suggestions for Future Research
Patton, T., Revill, P. A., Sculpher, M. J., & Bórquez, A. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2026969 · Cited by 8
Impact of cannabis on non-medical opioid use and symptoms of posttraumatic stress disorder: a nationwide longitudinal VA study
De Aquino, J. P., Sofuoglu, M., Stefanovics, E. A., & Rosenheck, R. A. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1818248 · Cited by 6
Characteristics and quality of life of people living with comorbid disorders in substance use recovery residences
Obekpa, E. O., McCurdy, S., Gallardo, K. R., Rodriguez, S. A., Cazaban, C. G., Brown, H. S., Yang, J. J., & Wilkerson, J. M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1412934 · Cited by 6
Associations of cannabis use, opioid use, and their combination with serious psychological distress among Ontario adults
Nigatu, Y. T., Elton‐Marshall, T., Mann, R. E., & Hamilton, H. A. (2021) · Stress and Health · doi:10.1002/smi.3071 · Cited by 6
Similar COVID-19 incidence to the general population in people with opioid use disorder receiving integrated outpatient clinical care
Vallecillo, G., Fonseca, F., Oviedo, L., Durán, X., Martinez, I., Garcia-Guix, A., Castillo, C., Torrens, M., Llana, S., Roquer, A., et al. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100027 · Cited by 5
Substance use disorder screening and brief intervention in routine clinical practice in specialist adult mental health services: A systematic review
Reilly, J., Meurk, C., Heffernan, E., & Sara, G. E. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221148394 · Cited by 7
The importance of social risk factors for patients diagnosed with opioid use disorder
Arsene, C., Na, L., Patel, P. M., Vaidya, V., Williamson, A. A., & Singh, S. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.02.016 · Cited by 5
Analgesic Use Among Adults with a Trauma-Related Emergency Department Visit: A Retrospective Cohort Study from Alberta, Canada
Sevcik, B., Lobay, K., Luu, H., Martins, K. J. B., Vu, K. N., Nguyen, P. U., Bohlouli, S., Eurich, D. T., Lester, E., Williamson, T. S., et al. (2023) · Pain and Therapy · doi:10.1007/s40122-023-00521-1 · Cited by 6
Insights into a Recovery Community Center Model: Results from Qualitative Interviews with Staff and Member Facilitators from Recovery Cafe in Seattle, Washington
Owens, M. D., Banta‐Green, C. J., Newman, A., Marren, R., & Takushi, R. Y. (2022) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2022.2088323 · Cited by 6
Analyzing Online Reviews of Substance Use Disorder Treatment Facilities in the USA Using Machine Learning
Agarwal, A. K., Guntuku, S. C., Meisel, Z. F., Pelullo, A., Kinkle, B., & Merchant, R. M. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06618-7 · Cited by 5
ILC-OPI: impulsive lifestyle counselling versus cognitive behavioral therapy to improve retention of patients with opioid use disorders and externalizing behavior: study protocol for a multicenter, randomized, controlled, superiority trial
Hesse, M., Thylstrup, B., Karsberg, S., Pedersen, M. M., & Pedersen, M. U. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03182-6 · Cited by 5
Patterns of health care interactions of individuals with alcohol use disorder: A latent class analysis
Phillips, A. Z., Wang, Y., & Allen, N. B. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209251 · Cited by 4
Gender and racial/ethnic differences in physiologic responses in the Stimulant Reduction Intervention using Dosed Exercise Study
Killeen, T. K., Wolf, B. J., Greer, T. L., Carmody, T. J., Rethorst, C. D., & Trivedi, M. H. (2020) · Addictive Behaviors · doi:10.1016/j.addbeh.2020.106546 · Cited by 4
Inducing Effects of Illegal Drugs to Improve Mental Health by Self-Regulation Therapy: A Pilot Study
Amigó, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910387 · Cited by 4
How Different Pre-existing Mental Disorders and Their Co-occurrence Affects COVID-19 Clinical Outcomes? A Real-World Data Study in the Southern United States
Qiao, S., Zhang, J., Chen, S., Olatosi, B., Hardeman, S. M., Narasimhan, M., Bruner, L., Diédhiou, A., Scott, C. L., Mansaray, A., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.831189 · Cited by 4
Impacts of the COVID-19 Pandemic on a Rural Opioid Support Services Program
Walters, J. E., Jones, A. E., Brown, A., & Wallis, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191811164 · Cited by 4
Long-COVID impacts taste and olfactory in individuals with substance use disorder: A retrospective cohort study from the TriNetX US Collaborative Networks
Tsai, R., Gau, S., Ho, Y., Lin, S.-Y., Ku, C.-Y., Wang, S., & Wei, J. C. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115970 · Cited by 5
The impact of the COVID-19 lockdown on services for substance use in Denmark: Implications for meeting users’ needs and recommendations for the future
del Palacio‐González, A., Thylstrup, B., & Houborg, E. (2022) · Nordic Studies on Alcohol and Drugs · doi:10.1177/14550725211069229 · Cited by 4
Assessment of knowledge, attitude, and practice of undergraduate medical students towards drug addiction and prevalence of drug addicts in Faculty of Medicine, University of KhartoumPreprint
Bashir, S. N., Hasabo, E. A., hag, N. E. E., Ahmed, Y. S., Omer, A. T., Abdelgadir, I. I., & Awadalla, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1374414/v1 · Cited by 4
Genetic associations among internalizing and externalizing traits with polysubstance use among young adultsPreprint
Brick, L. A. D., Benca‐Bachman, C. E., Johnson, E. C., Gustavson, D. E., Carper, M. M., & Palmer, R. H. C. (2023) · medRxiv · doi:10.1101/2023.04.04.23287779 · Cited by 5
Substances of abuse and their effect on SAR-CoV-2 pathogenesis
Antwi, I., Watkins, D., Pedawi, A., Ghrayeb, A., de Vuurst, C. V., & Cory, T. J. (2023) · NeuroImmune Pharmacology and Therapeutics · doi:10.1515/nipt-2023-0004 · Cited by 3
Integration of primary care into the substance use disorder outpatient treatment setting
Wasserman, R., & Terrien, J. (2020) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000432 · Cited by 3
Factors Associated With Leaving Against Medical Advice From Inpatient Substance Use Detoxification Treatment
Shirendeb, U. P., Lin, M., Fogel, J., Parrill, A., Bishev, D., Takhi, M., Joshaghani, H., Korie, I., Branch, R., Ioannou, C., et al. (2021) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0000000000000291 · Cited by 3
SEROPREVALENCE OF HBsAg, Anti-HBs, Anti-HCV, and Anti-HIV IN PATIENTS WITH ALCOHOL AND SUBSTANCE ABUSE IN AN AMATEM CLINIC IN EASTERN TURKIYE: A SIX-YEAR RETROSPECTIVE EVALUATION
Öner, P., Yılmaz, S. A., Kılıç, N., & Özsoy, F. (2022) · Journal of Contemporary Medicine · doi:10.16899/jcm.1189072 · Cited by 3
Palliative care for people with substance use disorders: a qualitative study of the experiences of rural primary care providers
Tayba, L., Cuesta‐Briand, B., Auret, K. A., & Coleman, M. (2025) · BMC Palliative Care · doi:10.1186/s12904-025-01828-w · Cited by 2
Defining Cannabis Use Disorder in Administrative Health Data: A Systematic Review of Case Definitions and Validation Approaches
Bahji, A., Alemi, M. I., Messier, G. G., & Patten, S. B. (2026) · Cannabis and Cannabinoid Research · doi:10.1177/25785125261437621 · Cited by 2
Prescribing Psychotropics: Misuse, Abuse, Dependence, Withdrawal and Addiction
(2021) · Frontiers research topics · doi:10.3389/978-2-88966-940-0 · Cited by 2
Similarities and Differences in Alcohol & Other Drug Dependence Among Hispanic/Latino Subgroups: A Disaggregation Approach
Correa-Fernández, V., Barazi, A. M., Chandra, M., & Anthony, J. C. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100124 · Cited by 2
Western Australia remote aeromedical substance use disorders outcomes
Faint, N., Coleman, M., Spring, B., Richardson, A., Thornton, A., Bacon, D., Kumaradevan, S., & Gardiner, F. W. (2023) · Internal Medicine Journal · doi:10.1111/imj.16140 · Cited by 2
Giving Voice to Women with Substance Use Disorder: Findings from Expressive Writing About Trauma
Jallo, N., Kinser, P. A., Eglovitch, M., Worcman, N., Webster, P., Alvanzo, A. A. H., Svikis, D. S., & Meshberg‐Cohen, S. (2024) · Women s Health Reports · doi:10.1089/whr.2023.0173 · Cited by 2
An audit of the cervical screening programme in the National Drug Treatment Centre (NDTC)
Haran, M., Kelly, J. R., Kennedy, L., Hennigan, K., Farid, H., Herteu, C., Kreisel, A., Salehin, S., Sullivan, M. O., Keating, S., et al. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02459-1 · Cited by 2
Prevalence of Opioid Misuse Risk in Patients With Cancer
Dannenberg, M. D., BRUCE, M. L., Barr, P. J., & Broglio, K. (2022) · Clinical journal of oncology nursing · doi:10.1188/22.cjon.261-267 · Cited by 2
Association Between Online Reviews of Substance Use Disorder Treatment Facilities and Drug-Induced Mortality Rates: Cross-Sectional Analysis
Abrams, M. P., Merchant, R. M., Meisel, Z. F., Pelullo, A., Guntuku, S. C., & Agarwal, A. K. (2023) · JMIR AI · doi:10.2196/46317 · Cited by 2
Buprenorphine Treatment and Patient Use of Health Services after the Affordable Care Act in an Integrated Health Care System
Campbell, C. I., Parthasarathy, S., Young‐Wolff, K. C., & Satre, D. D. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1305519 · Cited by 2
Self-citation
Hepatitis C treatment in patients with substance use disorder: the faster the better
Saviano, A., Héroin, L., Mayer, P., & Baumert, T. F. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-507 · Cited by 2
Naturalistic drug cue reactivity in heroin use disorder: orbitofrontal synchronization as a marker of craving and recoveryPreprint
Kronberg, G., Ceceli, A. O., Huang, Y., Gaudreault, P., King, S. G., McClain, N. E., Nelly Alia-klein, A., & Goldstein, R. Z. (2023) · medRxiv · doi:10.1101/2023.11.02.23297937 · Cited by 2
Addressing True Health Disparities: The Imperative of Telehealth and Telemental Health Services for Rural Americans
Lang‐Lindsey, K. (2024) · Biomedical engineering · doi:10.5772/intechopen.1004587 · Cited by 1
Forgone healthcare for medically vulnerable groups during the pandemic era: experiences of family caregivers of young adults with substance use disorders in Zambia
Kabembo, I. M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1250608 · Cited by 1

Authors: Bahorik, A. L., Satre, D. D., Kline-Simon, A. H., Weisner, C. M., & Campbell, C. I.
Affiliations: University of California, San Francisco (US)
Corresponding author: Bahorik, Amber L.
ORCID: Bahorik, Amber L.
Satre, Derek D.
Weisner, Constance M.
Campbell, Cynthia I.
Venue: Journal of Addiction Medicine
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2017-01
Volume: 11
Issue: 1
Pages: 3-9
ISSN: 1932-0620 (ISSN-L)
1935-3227
DOI: 10.1097/adm.0000000000000260
PMC: PMC5291754
OpenAlex: W2518262606
Cited by: 126
References: 33
Citations by year: 2026: 4 · 2025: 3 · 2024: 14 · 2023: 22 · 2022: 25 · 2021: 21 · 2020: 20 · 2019: 8 · 2018: 4 · 2017: 5
FWCI: 5.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Addiction Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institute on Drug Abuse (T32DA007250)
Topics: Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
Keywords: substance use disorders, alcoholism, cannabis use disorder, opioid use disorder, disease burden, comorbidities, Charlson Comorbidity Index, mortality risk, integrated care, privately insured patients
MeSH terms: Adult, California, Marijuana Abuse, Female, Humans, Male, Middle Aged, Mortality, Opioid-Related Disorders, Comorbidity, Delivery of Health Care, Integrated, Alcohol-Related Disorders, Electronic Health Records

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alcohol, Cannabis, and Opioid Use Disorders, and Disease Burden in an Integrated Health Care System

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks